Gastrointestinal Cancer clinical trials

Explore recruiting gastrointestinal cancer clinical trials.

Recruiting gastrointestinal cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Gastrointestinal Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis from Gastrointestinal cancer: a phase I study.

Belgium

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Oxaliplatin-based Chemotherapy for Treatment of Gastrointestinal, Pancreatic, or Colorectal Cancer (RECITE)

Spain, Portugal, France, Italy, Romania, Greece +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Anti-PD-1, Capecitabine, and Oxaliplatin for the first-line treatment of dMMR esophagogastric cancer (AuspiCiOus-dMMR): a proof-of-principle study

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Total Neoadjuvant Therapy for lymph node-positive adenocarcinoma of the OESophagus and oesophagogastric junction: TNT-OES-2 trial

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1 open-label, first-in-human, multi-center, dose escalation and dose expansion study of CLN-619 administered alone or in combination with pembrolizumab in patients with advanced solid tumors.

Spain, Poland

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients with Advanced Malignancies Associated with EphA2 Expression

Spain, Belgium

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Gastrointestinal Cancer trials by city

Gastrointestinal Cancer in Toronto Gastrointestinal Cancer in Vancouver Gastrointestinal Cancer in Montreal Gastrointestinal Cancer in Calgary Gastrointestinal Cancer in Edmonton Gastrointestinal Cancer in Ottawa Gastrointestinal Cancer in Winnipeg Gastrointestinal Cancer in Quebec City Gastrointestinal Cancer in Hamilton Gastrointestinal Cancer in Kitchener Gastrointestinal Cancer in London Gastrointestinal Cancer in Halifax Gastrointestinal Cancer in New York Gastrointestinal Cancer in Los Angeles Gastrointestinal Cancer in Chicago Gastrointestinal Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease